Application Note
For ELISA: Use at a concentration of 0.3 μg/ml. For WB: Use at a concentration of 0.1-0.5 μg/ml. Optimal dilutions/concentrations should be determined by the researcher.
Product Note
Reacts with natural and recombinant human Serum Amyloid A (SAA) and does not cross-react with other human cytokines or growth factors tested such as IL-1beta, IL-8, MCAF, TGF-beta and EGF.
Form
Liquid
Buffer
PBS
Preservative
No preservative
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
0.5 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Highly purified recombinant human serum amyloid A (MW: 12 kDa)
Purification
Protein G affinity purified
Conjugation
Unconjugated
RRID
AB_367632
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
Serum Amyloid A1 , Pig4 , Saa , Saa2 , Tp53I4 , Saa1
Background
The serum amyloid A (SAA) family comprises a number of differentially expressed lipoproteins, acute-phase SAA1 and SAA2, the former being a major component in plasma, and constitutive SAA's (C-SAAs). Although the liver is the primary site of synthesis of both SAA types, extrhepatic production has been reported. The in-vivo concentrations increase by as much as 1000 fold during inflammation. Several studies have expressed it's importance in the diagnosis and monitoring of various diseases. Pathological SAA values are often detected in association with normal CRP concentrations. SAA rises earlier and more sharply than CRP.
Research Area